Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Aug 25

PMID 30139042

Citations 104

Authors

Imadeldin Elfaki

Rashid Mir

Fahad M Almutairi

Faisel M Abu Duhier

Affiliations

Soon will be listed here.

Abstract

Cytochromes P450s (CYPs) constitute a superfamily of enzymes that catalyze the metabolism of drugs and other substances. Endogenous substrates of CYPs include eicosanoids, estradiol, arachidonic acids, cholesterol, vitamin D and neurotransmitters. Exogenous substrates of CYPs include the polycyclic aromatic hydrocarbons and about 80% of currently used drugs. Some isoforms can activate procarcinogens to ultimate carcinogens. Genetic polymorphisms of CYPs may affect the enzyme catalytic activity and have been reported among different populations to be associated with various diseases and adverse drug reactions. With regard of drug metabolism, phenotypes for CYP polymorphism range from ultrarapid to poor metabolizers. In this review, we discuss some of the most clinically important CYPs isoforms (CYP2D6, CYP2A6, CYP2C19, CYP2C9, CYP1B1 and CYP1A2) with respect to gene polymorphisms and drug metabolism. Moreover, we review the role of CYPs in renal, lung, breast and prostate cancers and also discuss their significance for atherosclerosis and type 2 diabetes mellitus.

Citing Articles

polymorphism rs1065852 significantly increases the risk of type 2 diabetes.

Wei H, Zhao Q Ann Med. 2025; 57(1):2470956.

PMID: 40028882 PMC: 11878161. DOI: 10.1080/07853890.2025.2470956.

Heterogeneity in Cancer.

MacDonald W, Purcell C, Pinho-Schwermann M, Stubbs N, Srinivasan P, El-Deiry W Cancers (Basel). 2025; 17(3).

PMID: 39941808 PMC: 11816170. DOI: 10.3390/cancers17030441.

The Functional Identification of the Gene in the Kidney of .

Shao D, Sheng K, Chao B, Tong Y, Jiang R, Zhang J Int J Mol Sci. 2025; 26(2).

PMID: 39859169 PMC: 11764603. DOI: 10.3390/ijms26020453.

Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome-An Update.

Elfaki I, Mir R, Elnageeb M, Hamadi A, Alharbi Z, Bedaiwi R Medicina (Kaunas). 2025; 61(1).

PMID: 39859066 PMC: 11767019. DOI: 10.3390/medicina61010083.

Engineering the microenvironment of P450s to enhance the production of diterpenoids in .

Cheng Y, Luo L, Tang H, Wang J, Ren L, Cui G Acta Pharm Sin B. 2024; 14(10):4608-4618.

PMID: 39525594 PMC: 11544389. DOI: 10.1016/j.apsb.2024.05.019.

References

Murray G, Patimalla S, Stewart K, Miller I, Heys S . Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010; 57(2):202-11. DOI: 10.1111/j.1365-2559.2010.03606.x. View

Su T, Bao Z, Zhang Q, Smith T, Hong J, Ding X . Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000; 60(18):5074-9. View

Yamada Y, Matsuo H, Watanabe S, Kato K, Yajima K, Hibino T . Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Int J Mol Med. 2007; 20(5):703-7. View

Li T, Matozel M, Boehme S, Kong B, Nilsson L, Guo G . Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011; 53(3):996-1006. PMC: 3079544. DOI: 10.1002/hep.24107. View

Guengerich F . Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol. 2007; 21(4):163-8. DOI: 10.1002/jbt.20174. View

Rai R, Sharma K, Misra S, Kumar A, Mittal B . CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users. Tumour Biol. 2014; 35(7):6531-7. DOI: 10.1007/s13277-014-1876-2. View

Moorthy B, Chu C, Carlin D . Polycyclic aromatic hydrocarbons: from metabolism to lung cancer. Toxicol Sci. 2015; 145(1):5-15. PMC: 4408964. DOI: 10.1093/toxsci/kfv040. View

Pikuleva I, Waterman M . Cytochromes p450: roles in diseases. J Biol Chem. 2013; 288(24):17091-8. PMC: 3682515. DOI: 10.1074/jbc.R112.431916. View

Leskela S, Honrado E, Montero-Conde C, Landa I, Cascon A, Leton R . Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer. 2007; 14(3):645-54. DOI: 10.1677/ERC-07-0078. View

10.

McFadyen M, Melvin W, Murray G . Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 2004; 3(3):363-71. View

11.

Ding G, Xu W, Liu H, Zhang M, Huang Q, Liao Z . CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. Mol Biol Rep. 2013; 40(5):3483-91. DOI: 10.1007/s11033-012-2423-0. View

12.

Yano J, Hsu M, Griffin K, Stout C, Johnson E . Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol. 2005; 12(9):822-3. DOI: 10.1038/nsmb971. View

13.

Baker R, Hayden M, Ghosh S . NF-κB, inflammation, and metabolic disease. Cell Metab. 2011; 13(1):11-22. PMC: 3040418. DOI: 10.1016/j.cmet.2010.12.008. View

14.

Ma M, Woo M, McLeod H . Genetic basis of drug metabolism. Am J Health Syst Pharm. 2002; 59(21):2061-9. DOI: 10.1093/ajhp/59.21.2061. View

15.

Luoma P . Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann Med. 2007; 39(5):359-70. DOI: 10.1080/07853890701379767. View

16.

Reynald R, Sansen S, Stout C, Johnson E . Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem. 2012; 287(53):44581-91. PMC: 3531772. DOI: 10.1074/jbc.M112.424895. View

17.

Port J, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt P . Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004; 25(11):2275-81. DOI: 10.1093/carcin/bgh243. View

18.

Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K . Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013; 28(4):332-8. DOI: 10.2133/dmpk.dmpk-12-rg-129. View

19.

Sanford J, Guo Y, Sadee W, Wang D . Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact. 2013; 28(1):23-30. PMC: 3755489. DOI: 10.1515/dmdi-2012-0038. View

20.

de Montellano P . Hydrocarbon hydroxylation by cytochrome P450 enzymes. Chem Rev. 2009; 110(2):932-48. PMC: 2820140. DOI: 10.1021/cr9002193. View